Sotrastaurin
Alternative Names: AEB 071; NVP-AEB071; Sotrastaurin acetateLatest Information Update: 28 Jul 2021
At a glance
- Originator Novartis; Ohio State University
- Developer Novartis
- Class Antineoplastics; Piperazines; Pyrroles; Quinazolines; Small molecules
- Mechanism of Action Protein kinase C inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Diffuse large B cell lymphoma; Uveal melanoma
- Discontinued Liver transplant rejection; Psoriasis; Renal transplant rejection; Transplant rejection; Ulcerative colitis; Uveitis
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for phase-I development in Uveal-melanoma(Metastatic disease) in France (PO)
- 28 Jul 2021 No recent reports of development identified for phase-I development in Uveal-melanoma(Metastatic disease) in Netherlands (PO)
- 28 Jul 2021 No recent reports of development identified for phase-I development in Uveal-melanoma(Metastatic disease) in United Kingdom (PO)